TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
U.S. Job Market Braces for Slow Recovery Amid Middle East Tensions and Economic Uncertainty 
Gold Prices Drop as Trump Escalates Iran Threats, Oil Surges 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Gold Prices Rebound But Head for Worst Month Since 2008 Amid Iran War Uncertainty 
Japan Signals Readiness to Intervene as Yen Weakens Toward 160 Per Dollar 
Gulf War Ceasefire Hopes Weigh on Dollar Ahead of Trump Address 
U.S. Stock Futures Steady Amid Iran Ceasefire Talks and Trump Address 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Australia's Trade Surplus Surges in February on Gold Export Boom 
Oil Prices Climb as Middle East Conflict Keeps Supply Risks Elevated 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Escalation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Medicago Inc. has been developing a plant-based vaccine for COVID-19, and for this project, it has teamed up with some companies, including Philip Morris. The World Health Organization recently rejected its vaccine and with this, the Canadian biotechnology company decided to sever ties with the cigarette maker.
According to Bloomberg, Medicago submitted a request for the emergency-use listing of its plant-based COVID-19 vaccine but WHO did not grant its approval earlier this year. It was reported that the reason for the rejection was the biotech firm’s links with the tobacco industry.
Medicago made Covifenz which was dubbed as the first plant-based COVID vaccine in the world. It was jointly developed by Medicago and GlaxoSmithKline but the Canadian government contributed to the funding of its development by providing $173 million. The Canadian biotech firm is also 25% owned by Philip Morris.
However, despite the successful tests and approval from Health Canada, WHO gave the opposite decision; thus, it cannot be shipped anywhere else. This outcome pushed Medicago to drop Philip Morris from the COVID-19 vaccine collaboration.
The company’s move to eject the cigarette maker from the project was highly praised by civil society, and proceeded to plead with all governments to avoid working with tobacco companies in the future.
"Tobacco corporations, vaccines and governments do not mix well and we applaud the expulsion of Philip Morris from the Medicago collaboration," executive director of the non-profit organization Action on Smoking & Health (ASH) Canada, Les Hagen, said in a press release. "Tobacco industry products are responsible for over eight million deaths annually worldwide and tobacco corporations are desperately trying to whitewash their terrible public image by investing in the health sector.”
Hagen added that they are pleased that Canadian governments have decided to not get involved with a company in the tobacco business any longer. He also described the initial partnership as an “unethical and embarrassing collaboration with a tobacco giant."
Corporate Accountability's tobacco campaign director, Daniel Dorado, added, "Now that Philip Morris has been ejected from this collaboration, we urge Canadian governments to fully comply with the treaty by closing the barn door on any future tobacco industry partnerships."
